• Live demonstration of new software at Heart Rhythm Society (HRS) 2023, May 19-21
MARSEILLE, France, May 18, 2023 (GLOBE NEWSWIRE) -- Volta Medical, a pioneering health technology company developing artificial intelligence (AI) solutions to assist electrophysiologists in treating complex cardiac arrhythmias such as atrial fibrillation (AF), today announced that the U.S. Food and Drug Administration (FDA) has cleared Volta AF-Xplorer™, an AI companion designed for the assessment of complex AF and atrial tachycardia (AT) procedures. The company will showcase the latest solution at the 44th annual Heart Rhythm 2023, in New Orleans, LA, and virtually, from May 19-21.
“There is a critical need for new ways to quickly and accurately identify abnormal electrograms (EGMs) for cardiac electrophysiologists to optimize their ablation strategy. Volta AF-Xplorer offers a tailored and intuitive workflow while allowing physicians to use their preferred mapping system and catheter,” said Theophile Mohr-Durdez, Volta Medical CEO and co-founder. “Volta AF-Xplorer assists physicians in the treatment of complex AF cases by providing real-time access to expert electrophysiologist techniques for detecting dispersed EGMs, suspected drivers of AF.”
Volta AF-Xplorer uses a machine and deep learning-based algorithm trained on a large database of EGMs, annotated by expert electrophysiologists. This approach enables a real-time, standardized approach to targeting dispersed EGMs. The software upgrade features an enhanced integration with Abbott Laboratories’ EnSite X mapping system, providing improved workflow due to automated Volta “regions of interest” tagging capabilities. In addition, the software provides compatibility with Biosense Webster’s popular Octaray multi-polar mapping catheter.
In a previously published multi-center clinical study, Volta’s solution has demonstrated the ability to standardize the use of dispersed EGMs to guide ablation and achieve clinical outcome measures, including freedom from arrhythmia after 12 months that meaningfully exceed conventional outcomes. Recently, Volta completed enrollment of TAILORED-AF, a global multicenter randomized controlled trial, comparing conventional pulmonary vein isolation to pulmonary vein isolation plus Volta’s guided ablation in 374 patients with persistent and long-standing persistent AF.
At HRS, the Volta Medical Heart Rhythm Theater presentation, “Could Targeting AI Driven Dispersion EGMs Be the Missing Link for Better Persistent AF Outcomes?”, will take place on Saturday, May 20, from 9:15-10:15am CT, including a review of Volta cases, current and future clinical evidence, and AI considerations. It will be moderated by Dr John Hummel, Ohio State University, with presentations from Drs. Devi Nair, St Bernard’s Jonesboro, Jose Osorio, HCA Miami, Benjamin D’Souza, Penn Presbyterian, and Prof. Isabel Deisenhofer, Munich Heart Center.
In addition, the company will present the poster: “Biatrial Characterization of AI Identified Spatiotemporal Dispersion in Persistent Atrial Fibrillation (poster presentation)” from 1:30-3:30pm CT, on Saturday, May 20, which highlights the uniqueness of patterns of dispersion EGMs to each patient in the analysis done within the previously published, Ev-AIFib study.
The Volta Medical booth (#1340) will feature a demonstration of the Volta AF-Xplorer software.
Hosted by the Heart Rhythm Society, Heart Rhythm 2023 brings together the world’s leading clinicians, scientists, researchers, and innovators to exchange ground-breaking science to improve the care of arrhythmia patients.
About the TAILORED-AF Trial
TAILORED-AF is an international, multicenter trial designed to determine if a tailored VX1 AI software-guided ablation strategy targeting areas of spatiotemporal dispersion in combination with pulmonary vein isolation (PVI) is superior to a conventional anatomical ablation strategy targeting PVI alone for the treatment of persistent AF. The primary endpoint of the study is the absence of documented AF episodes > 30 seconds, with or without anti-arrhythmic drugs (AADs), 12 months after a single index ablation procedure. Secondary endpoints include absence of AF and/or atrial tachycardia (AT) episodes after a 12-month period, following one or more procedures, as well as safety. Volta Medical expects results from the TAILORED-AF trial in 2024.
About Volta Medical
Volta Medical is a health technology company developing artificial intelligence software solutions to assist cardiac electrophysiologists during arrhythmia treatment procedures to improve clinical outcomes for patients. Founded by three physicians and a data scientist in 2016 in Marseille, Volta’s overarching goal is to improve cardiac arrhythmia management by developing state-of-the-art, data-driven medical devices trained on large databases of procedural data with the highest standards of data protection. The company’s first product, VX1, is a digital AI companion device and algorithm to assist cardiologists with real-time identification of specific abnormal electrograms, known as dispersed EGMs. Its second software iteration, Volta AF-Xplorer is now cleared for use in the US and is pending CE-mark for use in the EU. For more information, visit the company’s website at www.volta-medical.com.
Media Contact
Jeff Martin, VP of Global Marketing
Volta Medical
jeffrey.martin@volta-medical.com
U.S. Media Contact
Glenn Silver
Finn Partners
glenn.silver@finnpartners.com
